UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
[X] Annual Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934. For the fiscal year ended December 31, 1996.
[ ] Transition Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934. For the transition period from
____________ to _______________.
Commission file number 0-23666
Tripos, Inc.
(Exact name of registrant as specified in its charter)
Utah 43-1454986
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
1699 S. Hanley Rd, St. Louis, MO 63144
(Address of principal executive offices) Zip Code
Registrant's telephone number, including area code:
(314) 647-1099
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Name of each exchange
on which registered:
None None
Securities registered pursuant to Section 12(g) of the Act:
Common stock, $.01 Par Value
(Title of class)
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes X No __.
Indicate by check mark if disclosure of delinquent filers pursuant
to Item 405 of Regulation S-K is not contained herein, and will not
be contained, to the best of registrant's knowledge, in definitive
proxy or information statements incorporated by reference in Part
III of the Form 10-K or any amendment to this Form 10-K [X].
The aggregate market value of the voting stock held by non-
affiliates of the Registrant as of March 21, 1997, was $43,489,996
based upon the March 21, 1997 closing price for shares of the
Registrant's Common Stock as reported by the NASDAQ National
Market). Shares of Common Stock held by each officer, director and
holder of 5% or more of the outstanding Common Stock have been
excluded in that such persons may be deemed to be affiliates. This
determination of affiliate status is not necessarily a conclusive
determination for other purposes.
On March 21, 1997, 3,049,175 shares of the Registrant's Common
Stock, $0.01 par value, were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
1. Portions of the Registrant's 1996 Annual Report to Shareholders
for the fiscal year ended December 31, 1996 are incorporated by
reference into Parts II and IV.
2. Portions of the Registrant's Proxy Statement for the Annual
Meeting of Shareholders to be held May 9, 1997 are incorporated by
reference into Part III.
Part I
Item 1.
Business
Tripos Inc., ("Tripos", the "Company" or the "Registrant"), is
a leader in discovery services, informatics and products for life
science organizations worldwide. Tripos' current proprietary
technologies and strategic relationships expand its reputation in
combinatorial chemistry for efficient pharmacological activity
prediction and analysis, a major factor in customersO cost-effective
new product success. Based on scientific expertise in these areas
as well as a worldwide sales and marketing organization, Tripos
expanded its business model in 1996. The Company now offers the
following products and services: software, systems integration,
technology transfer, screening libraries, contract discovery
research and risk based discovery research. The Company continues
to be a reseller of third party hardware products that are
compatible with the Company's software products.
Effective June 1, 1994, Evans & Sutherland Computer Corporation
("E&S") distributed all outstanding shares of Tripos, Inc. common
stock to E&S shareholders ("the Distribution"). Every three shares
of E&S yielded one share of the Company. Prior to the Distribution,
the Company was a wholly owned subsidiary of E&S.
The Company was originally incorporated in the state of
Missouri on October 29, 1979. The Company was reincorporated under
the laws of the State of Utah effective June 1, 1994. The Company
maintains its executive offices and principal facilities at 1699 S.
Hanley Rd., St. Louis, Missouri 63144. The Company also has wholly
owned subsidiaries with offices in Milton Keynes, England, Antony,
France, and Munich, Germany. There are two leased offices for sales
activities in Shrewsbury, New Jersey, and Redwood City, California.
Industry Background
The success of companies in the pharmaceutical, biotechnology,
chemical and agrochemical industries is substantially dependent upon
their ability to identify new pharmaceutical and chemical compounds
with targeted activities and properties which can be brought to
market rapidly and on a cost-effective basis. The discovery and
development of a new pharmaceutical or chemical product candidate
typically involves many investigative phases, including storage,
retrieval, analysis, review, communication, management and
manipulation of large volumes of information relating to chemical
structures and properties, molecular patterns, statistical
information, reactions involved in syntheses and biological
properties. Based on industry data, the average pharmaceutical
discovery process requires synthesis and testing of over 10,000
chemical compounds for each new product brought to market. The
Company's products are used primarily in the pre-clinical phases of
new pharmaceutical development, the equivalent pre-approval phase of
agrochemical product development and product discovery phases of
chemical research. These phases can represent up to 30% of the
expense of new product research and development.
Industry pressure to reduce product development cost and time
to market are in part attributable to increased competition and
increased political, regulatory and consumer scrutiny. By reducing
the time to market, pharmaceutical companies can generate billions
of dollars of additional profits. In addition, environmental
regulations and consumer activism are forcing chemical and
agrochemical companies to evaluate alternative products and means of
doing business, thereby increasing their product development and
operating costs. Through the use of effective discovery information
and analysis software in the key initial stages of new compound
research and development, companies in these industries may be able
to evaluate scientific data faster and more cost efficiently for the
creation of new chemical lead candidates.
Pharmaceutical and biotech companies have focused their R&D
efforts on both novel compounds exhibiting demonstrable benefits
over the existing commercial drug and novel targets, many of which
are emanating from work being done on the human genome project. To
this end, many companies are implementing high throughput screening
laboratories with robotic systems for the rapid analysis of large
numbers of compounds for biological activity. An outgrowth of this
development is the increased need for material to screen, or to
test. Companies are buying thousands of compounds a year to screen
in order to find a novel compound with the desired biological
activity. The Company believes it is positioned to provide these
compounds and their corresponding database through its collaboration
with Panlabs, Inc. of Bothell, Washington. By coupling compounds
with discovery informatics, Tripos offers its customers increased
discovery efficiencies.
Products
The Company offers its expertise for customer applications via
a complementary range of new compound discovery technologies in
software, chemical compound library, and consulting service options.
Discovery Software (Computational Chemistry)
The Company's software products collectively address the needs
of the customer organizations' new compound research team.
Standalone, client-server and new Web intranet applications are
variously employed depending on the requirements of the individual
research team members with an emphasis on easy analysis of complex
data results. At the team level, the products' integrated design
creates a collaborative discovery research environment by providing
convenient scientific data communication features and strategies.
Integrated Molecular Design, 3D Searching, and Analysis: This
integrated system of applications consists of SYBYL Molecular
Design, UNITY 3D Flexible Searching, TRIAD NMR Analysis, and other
related optional modules. These programs feature a shared data
environment compatible with heterogeneous distributed global
networks. The products are available on UNIX workstations from
Silicon Graphics. SYBYL provides research scientists with an
interactive tool for exploring the complex three-dimensional shapes
of molecules and the relationship between shape, structure, function
and activity. Understanding these relationships permits the
scientist to postulate new molecules which will have an enhanced
activity or property, or reduced adverse properties or side effects.
UNITY, introduced in 1993, was developed for chemical information
applications through a consortium of nine of the Company's
customers. It provides two-dimensional and three-dimensional
database searching of chemical structures, including three-
dimensional conformationally flexible matching. It can screen
hundreds of thousands of molecules in seconds for specified
patterns. TRIAD provides automated processing of nuclear magnetic
resonance ("NMR") spectral data from spectrometers. Its use with
SYBYL results in fast analysis of results to predict three-
dimensional molecular structures for visualization and analysis.
Such structures are important inputs to the molecular modeling
process and can serve as starting points for database searches.
Molecular Spreadsheet: The Molecular Spreadsheet functions as
the central communication tool environment for the scientist, and
promotes easy data analysis and graphical representation of results.
The format of the Molecular Spreadsheet is similar to that used in
popular business spreadsheets, providing a familiar environment for
the user. This familiarity accelerates the learning process and
allows the user to concentrate on solving research problems.
Scientists can use the Molecular Spreadsheet to combine the results
of database queries with general data manipulations, statistical
analyses and chemistry-specific computations to perform "what if"
analyses. This unifying feature is a significant differentiator for
the Company's products.
A new product, ChemEnlighten, which is expected to be released in
the second quarter of 1997, extends the paradigm of the Molecular
Spreadsheet by enabling the handling of spreadsheets containing
hundreds of thousands of compounds (rows). The product uses File
Based Tables and a JavaSheet viewer for Intranet Web browsers.
Analysis tools similar to those offered by the Molecular Spreadsheet
are currently under development.
Combinatorial Chemistry and Molecular Diversity: Legion,
Selector, and DiverseSolutions software offer specialized database
management and diversity analysis. The software is used to manage
the extremely high volumes of data created by high throughput
screening, to plan new experiments in combinatorial (high
throughput) synthesis and to interpret the results. The Company
meets customer demands for software complementing new technology
that screens and tests hundreds of thousands of chemical compounds
to see which ones show pharmaceutical or agrochemical activity.
Legion generates descriptions and databases of compound libraries
based on specified reactants and reactions. Selector analyzes the
structures and properties to produce predictive models that help
guide the search for new leads or to select subsets of larger
collections of compounds to speed Discovery research programs.
DiverseSolutions solves related problems in molecular diversity
analysis with the ability to rapidly search large data sets; it was
introduced in 1996.
Personal Computer Software Products: The Company offers
Alchemy 2000 and a number of associated modules. Completely rewritten
for release in 1996, Alchemy 2000 is designed for individual
scientists and students for molecular visualization, analysis, and
chemical property prediction. Alchemy 2000 works in the Microsoft
Windows operating environment. The ease of use and affordability of
Alchemy 2000 allows a larger number of academic and commercial
chemists and biologists to use molecular modeling. Several
companion application modules are currently offered as options to
the program. These options target specific research areas including
polymer, glass, protein, and statistical research.
These products range in price from $495 to $1,995 and contain
license management using software licensing codes or shrink wrap
format.
Web-based Software: The Company has developed a toolkit for
accessing its molecular design and database searching software via
customer Intranets. Many of the CompanyOs pharmaceutical customers
are investing heavily in development of internal computer networks
to provide software applications and services to their scientists.
The company is seeding that effort with servers and Java applets for
Web browsers in order to broaden the access to its products among
medicinal chemists. The Company began marketing this technology as
the Discovery.Net Club in 1996. Membership provides customers with
a significant lead in Intranet developments they would otherwise
undertake on their own. Additional servers and applets are under
development.
Discovery Services
Compounds: Recent advances in the area of high-throughput
screening (rapid screening of compounds for biological activity)
have given rise to the need for large numbers of compounds by both
pharmaceutical companies and biotechnology companies. These
companies routinely acquire thousands of compounds a year to screen
in search of novel classes of active compounds. By applying the
Company's compound design technology in conjunction with the
synthesis technology of Panlabs, Inc. (of Bothell, WA), the Company
has brought to market Optiverse, a diverse library of screening compounds.
This library provides an efficient source of compounds for screening by
removing redundant and ineffective samples from the screening
effort.
A key advantage of the Optiverse library is that each compound
is representative of a cluster of similar compounds numbering in the
thousands. When Optiverse compounds demonstrate activity in
pharmaceutical company assays, the Company and Panlabs can quickly
and efficiently provide hundreds of similar compounds for follow-up
screening and lead optimization.
ChemSpace: Tripos has developed unique and proprietary
technology for the storage and searching of vast numbers of
combinatorial products and related data. Using this technology,
Tripos has rapidly created a database of over 150 billion
synthetically accessible small organic chemical structures that are
searchable in real time at the rate of 500 million per hour. The
database can be customized to include reactions and compounds that
are proprietary to its customer base. Tripos is licensing this
technology to a limited number of pharmaceutical companies.
Consulting: The reforms in health care have forced
pharmaceutical companies to restructure their operations, including
their research programs. One of the results of this restructuring
is a significant emphasis on outsourcing and partnering on the part
of the large pharmaceutical companies with smaller technology
companies. At the same time, the rapid development of certain
technologies, including combinatorial chemistry and high throughput
screening, have forced many of the smaller pharmaceutical companies
and biotech companies to look to outside groups to provide needed
technology rather than invest in it themselves. This significant
trend in outsourcing has opened the opportunity for the Company to
offer its expertise to drug development organizations through
compound design, molecular analysis, and, in conjunction with
Panlabs, a complete suite of lead discovery and lead optimization
capabilities. Tripos leverages these capabilities by entering into
consulting service contracts with its customers.
Sales, Marketing and Distribution
The Company sells its software products directly in the U.S.
and Europe, through an exclusive distributor arrangement in Japan
with Sumisho Electronics Company, Ltd., and through non-exclusive
agency relationships in Korea with New Technics Co., Ltd., in Taiwan
with Scientek Corporation, in China and Singapore with 3-Link
Systems Pte. Ltd., and in India with iitSoft. On December 31, 1996,
the Company's sales force consisted of 40 management, technical,
sales and administrative employees: 17 for the United States and
Canada, 21 in Europe, and 2 for the Pacific Rim. The Company's
domestic sales and support center is located at its headquarters in
St. Louis, Missouri. The Company also maintains sales offices in
California and New Jersey. The Company has wholly owned subsidiaries
in suburbs of London, Paris and Munich.
For its software product lines for workstations, the Company
employs pre-sales and post-sales support scientists resident in the
United States, England, France, and Germany. These scientists,
working in collaboration with the Company's sales employees, have
developed a consultative sales approach through which the Company
has created relationships with its key customers. The Company
believes these relationships enable the Company to understand and
better serve the information management needs of its customers.
Because the Company's customers frequently have both domestic and
international operations, the Company's sales staff and scientists
in foreign locations work closely with their counterparts in the
United States to ensure that the customer's international needs are
met in a coordinated and consistent fashion.
The Company's workstation-based software products are sold in a
variety of ways, one of which is perpetual licenses on the basis of
a fixed number of simultaneous users per module. Network-based
licensing is available, based on a count of the number of
simultaneous users. The Company has also introduced one, two and
three year subscription service options that offer customers the
flexibility to change their product selections periodically and are
renewable at the end of the selected terms. The Company expects to
migrate its customer base to shorter-term license renewals based on
the flexibility to access all of its software products. This will
provide a predictable recurring revenue stream from periodic
renewals. Software packages consisting of modules typically
purchased by customers in particular industry segments have been
defined and have been specially priced to facilitate customer
purchase of an optimal module set for their problems.
Sales of the compound libraries are made through a staff
assigned to the product. Tripos has dedicated sales professionals
on the east and west coasts of the United States and in Europe. The
Optiverse library now includes over 80,000 compounds that are
available for purchase. The compounds are sold on a nonexclusive
basis to all purchasers and Tripos retains no trailing rights to the
compounds once they are purchased by a customer.
The Company's sales staff includes employees with Ph.D. degrees
in chemistry, various advanced degrees in the sciences and work
experience with various hardware and software suppliers as well as
with the industries served by the Company. The Company's sales
representatives are compensated through a combination of base
salary, commissions and bonuses based on quarterly and annual sales
performance. In addition, the Company's pre-sales scientists, all
of whom have Ph.D. degrees in chemistry or a closely related field,
receive a compensation determined in part by their success in
supporting and generating sales in a particular territory.
The Company exhibits its software at various scientific
conferences and trade exhibitions, including national and regional
conferences of the American Chemical Society and the Experimental
Nuclear Magnetic Resonance Conference. Company scientists
frequently publish and present results of original research at these
and other conferences throughout the world.
The Company sells its personal computer software products
principally through direct mail and relationships with distributors.
Customer Training, Service and Support
The Company's licenses typically provide a limited warranty for
a 90 day period. Thereafter, support of the Company's software
products is provided for an annual fee. Approximately 80% of the
Company's commercial customers and half of the Company's academic
customers have contracted for support service. This service gives
customers access to telephone consultation with the Company's
technical personnel in local offices, on-line access to a Company-
operated computer bulletin board, new release versions of licensed
software and other support required to utilize the Company's
products effectively.
The Company offers customer training in the use of its products
through staff knowledgeable in both chemistry and computer science.
The Company sends technical newsletters, bulletins, and advance
notification about future software releases to its customers to keep
them informed and to help them with resource allocation and
scheduling. The Company also sponsors seminars throughout the world
for its customers, involving presentations both by Company personnel
and guest lecturers. These seminars are designed to enhance
customer understanding of the Company's products and their potential
utilization as an aid to customer research requirements. The
Company currently provides its customers with advice on computer
system configuration management and frequently provides customers
with consulting advice in addressing particular research questions
as part of the normal pre- and post-sales process.
Product Development
The Company believes that its ability to maintain its
technological position in the molecular informatics market and to
continue development of the diverse compound library will depend in
large part on its ability to enhance its current product line,
develop new products, maintain technological competitiveness and
meet an evolving range of customer requirements. The Company
intends to continue to make substantial investments in product and
technology development to meet its customers' requirements.
The Company has previously experienced delays in developing new
products ranging from a few days to approximately twelve months.
The complexity of developing new and enhanced scientific information
management software in a client/server environment is significant.
Delays or unexpected difficulties in any segment of a development
project can result in late or undeliverable product. In view of
this complexity, there can be no certainty that the Company will be
able to introduce its products on a timely basis in the future, or
that the Company's new products and product enhancements will
adequately meet the requirements of the marketplace or achieve
market acceptance.
The Company's research and development activities are
undertaken by its Discovery Software Group and its Accelerated
Discovery Services Group. The Discovery Software Group, composed of
chemists and other scientists, works closely with customers to
identify market needs for new products. Upon identification of a
market need for a new product, the Discovery Software Group
collaborates with the Company's software engineers to develop
requirements and specifications, implement code and perform
regression tests for the new product. Separate quality assurance,
environment management and systems groups manage the final release,
documentation and porting of the new product to all supported
platforms. In addition, the Company funds research at certain
academic institutions. The Company believes that this funding
allows it to gain access to significant technology not otherwise
available. The Accelerated Discovery Services Group has its own
staff of scientists and programmers that are familiar with the
research techniques and goals of its customers.
Research and development expenses were $3.4 million, $3.6
million, and $3.4 million in 1994, 1995 and 1996, respectively.
Research and development expenses, including the amount of
capitalized costs were $4.3 million in 1994, $6.8 million in 1995
and $7.0 million in 1996 representing 22%, 32%, and 24% of net
sales, respectively. The Company capitalized $.9 million of product
development costs in 1994, $3.2 million in 1995 and $3.6 million in
1996. This represented 21%, 47% and 51% of total product research
and development expenditures in these periods. The Company
anticipates that its investment in new product research will
continue to be significant as Tripos invests in the growth of web-
based tools, desktop applications and combinatorial chemistry
software products. Likewise, investment continues on the diverse
compound libraries.
The Company has entered into consulting contracts with certain
customers which provide for collaboration with the Company in
customizing chemical compound libraries for drug discovery in
specific therapeutic areas. The Company recognizes revenue related
to such agreements as contractual milestones are achieved and
delivered or, absent such contractual milestones, on a completed
contract basis.
Tripos offers its customers a systems integration service by
which the Company builds customized systems solutions. Chemical
research teams require improved information access and usage in
their discovery process. The Company is helping its customers meet
these needs by applying its expertise in web technologies, chemical
information systems, and biological data handling to build
integrated systems designed specifically for the customer's
environment and discovery process.
Proprietary Rights
The Company relies primarily upon a combination of copyright,
trademark and trade secret laws and license and non-disclosure
agreements to establish and protect the proprietary rights in its
products. In addition, the Company has obtained one patent with
respect to its SYBYL QSAR product which expires June 18, 2008. The
source code for the Company's products is protected both as a trade
secret and as an unpublished, copyrighted work. In addition, the
Company's software products are developed and manufactured only at
its St. Louis facility and the Company does not disclose the source
code for its products to any of its subsidiaries or distributors.
The Company supplies its source code under special, restrictive
license provisions to customers on special request. All software
products are shipped from its St. Louis facility. Chemical compound
libraries are only manufactured and shipped by Panlabs, Inc. at its
Bothell, Washington location. Despite these precautions, it may be
possible for a third party to copy or otherwise obtain and use the
Company's products or technology without authorization, or to
develop similar technology independently. In addition, effective
copyright and trade secret protection may be unavailable or limited
in certain foreign countries where the Company does business.
Because the markets in which the Company competes are characterized
by rapid technological change, the Company believes that factors
such as the technological and creative skills of its personnel, new
product development, frequent product enhancements, name recognition
and reliable product maintenance are more important to establishing
and maintaining a technology leadership position than the various
legal protections of its technology.
The Company licenses its workstation software through the
execution of license agreements. The Company licenses its personal
computer software products by use of a "shrink wrap" license. A
"shrink wrap" license agreement is a printed license agreement
included within packaged software that sets forth the terms and
conditions under which the purchaser can use the product and is
intended to bind the purchaser, by the purchaser's acceptance of the
software, to such terms and conditions.
The Company has a number of contracts with academic
institutions and individuals providing the Company the right to
license, market and use technology developed outside the Company.
These products, while important for the Company's ability to offer
an enriched product line, do not represent a material percentage of
the Company's annual revenue.
Compound and consulting transactions require specific
agreements regarding defined proprietary rights, responsibilities of
the parties, and/or allowed use of any related compounds or
libraries of compounds.
Competition
The Company operates in a highly competitive industry
characterized by rapidly changing technology, frequent new product
introductions and enhancements, and evolving industry standards.
The Company competes with other vendors of software products
designed for applications in analytical chemistry, computational
chemistry, chemical information management, and combinatorial
chemistry; the four principal areas in the chemical and
pharmaceutical research market. The Company's Accelerated Discovery
Services Group competes with other vendors for the sale of contract
research and compound libraries.
Competition is likely to intensify as current competitors
expand their product offerings and as new companies enter the
market. The competition experienced by the Company in its existing
and targeted markets could result in price reductions, reduced
margins and loss of market share, all of which could have an adverse
effect on the Company. A number of the Company's existing
competitors have significantly greater financial, technical and
marketing resources than the Company. The Company believes that the
principal factors affecting competition in its markets are product
quality, performance, reliability, ease of use, technical service
and support, and price. It is expected that these factors will
remain major competitive issues in the future, but additional
factors will become increasingly important, including contribution
to the overall efficiency of the research effort through enhanced
integration, communication and analysis. Although the Company
believes that it currently competes favorably with respect to these
factors, there can be no assurance that the Company will be able to
compete successfully against current and future competitors or that
the competitive pressures faced by the Company will not have a
material effect on its business, operating results or financial
condition.
Production
The Company's production operations consist of assembling,
packaging and shipping the software and database products and
documentation needed to fulfill orders. Outside vendors provide CD-
ROM duplication, printing of documentation, manufacturing of
packaging materials and assembly of the Company's desktop products.
The Company typically ships its products promptly after the
acceptance of a customer purchase order and the execution of a
software license agreement. Accordingly, the Company does not
generally have any significant software backlog, and the Company
believes that backlog at any particular time, or fluctuations in
backlog, are not indicative of sales for any succeeding period.
Chemical compounds are designed by Tripos and manufactured by
Panlabs, Inc. at their Bothell, Washington facility. Compound sales
are shipped shortly after the execution of a sales contract between
the customer, Panlabs and Tripos. The potential for backlogs exists
in the delivery of compounds due to the nature of the materials to
be accumulated, packaged and shipped along with the sometimes
lengthy compound selection process of the customer. Backlogs will
fluctuate based on the number, size and timing of orders received.
Significant Customers
The Company does not derive 10% or more of its total sales from
any single customer.
International Sales
The Company sells its software products through its wholly
owned subsidiaries in Europe, through an exclusive distributor in
Japan, and through non-exclusive agency relationships in Singapore,
China, India, Korea, and Taiwan. Net sales from the Company's
activities outside of North America represented approximately 57%,
49% and 48% of the Company's total net sales in 1994, 1995, and
1996, respectively. Net sales in Europe accounted for 48%, 39% and
38% of the Company's net sales in 1994, 1995, and 1996,
respectively, with the balance from customers in the Pacific Rim.
The Company believes that revenues from its foreign activities will
continue to account for a significant percentage of its total net
sales. See Note 8 to the consolidated financial statements,
Geographic Segment Data, in the Company's Annual report.
Employees
As of December 31, 1996, the Company had a total of 122
employees, of whom 100 were based in the United States and 22 were
based internationally. Of that total, 62 were engaged in marketing,
sales and related customer-support services, 45 in product
development and 15 in operations, administration and finance. The
Company's future success is significantly dependent on the continued
service of its key technical and senior management personnel and its
continuing ability to attract and retain highly qualified technical
and managerial personnel. None of the Company's employees are
represented by a labor union nor covered by a collective bargaining
agreement. The Company has not experienced any work stoppages and
considers its relations with employees to be good.
Executive Officers and Key Employees
The information required by this item is included in the
Company's Proxy Statement in connection with its Annual Meeting of
Shareholders to be held on May 9, 1997 under the caption
"Management", and is incorporated herein by reference.
Item 2. Properties
The Company's principal administrative, sales, marketing and
product development facilities are located in St. Louis, Missouri.
These facilities are leased through August 31, 2000. The Company
leases two other domestic sales and service offices in Shrewsbury,
New Jersey and Redwood City, California. The Company's European
subsidiaries lease sales and service offices in the United Kingdom,
France and Germany. The Company believes that its existing
facilities are adequate for its current needs and that additional
space will be available as needed.
Item 3. Legal Proceedings
The Company is currently not a party to any material litigation
and is currently not aware of any pending or threatened litigation
that could have any material adverse effect upon the Company's
business, operating results or financial condition.
Item 4. Submission of Matters to a Vote of Security Holders
No matters were submitted to a vote of the Company's
shareholders during the fourth quarter of its fiscal year ended
December 31, 1996.
Part II
Item 5. Market for Registrant's Common Stock and Related
Shareholder Matters
The information required by this item is set forth on page 32
of the Company's 1996 Annual Report to Shareholders and is
incorporated herein by reference.
Item 6. Selected Financial Data
The information required by this item is set forth on page 30
of the Company's 1996 Annual Report to Shareholders and is
incorporated herein by reference.
Item 7. Management's Discussion and Analysis of Financial
Condition and Results of Operations
The information required by this item is set forth on pages 13
through 17 of the Company's 1996 Annual Report to Shareholders and
is incorporated herein by reference.
Item 8. Financial Statements and Supplementary Data
The consolidated financial statements and supplementary
financial information required by this item are set forth on pages
18 through 28 of the Company's 1996 Annual Report to Shareholders
and are incorporated herein by reference.
Item 9. Changes in and Disagreements with Accountants on
Accounting and Financial Disclosure
None.
Part III
Item 10. Directors and Officers of the Registrant
The information required by this item is included under the
captions "Election of Directors" and in the Company's Proxy
Statement in connection with its Annual Meeting of Shareholders to
be held on May 9, 1997 and is incorporated herein by reference. The
information required by this item relating to the Company's
executive officers and key employees is included in the Company's
Proxy Statement under the caption "Management" and is incorporated
herein by reference.
Item 11. Executive Compensation
The information required by this item is included under the
caption "Executive Compensation and Related Information", except for
the Report of the Compensation Committee or the Comparison of
Shareholder Return, in the Company's Proxy Statement in connection
with its Annual Meeting of Shareholders to be held on May 9, 1997
and is incorporated herein by reference.
Item 12. Security Ownership of Certain Beneficial Owners and
Management
The information required by this item is included under the
caption "Ownership of Securities" in the Company's Proxy Statement
in connection with its Annual Meeting of Shareholders to be held on
May 9, 1997 and is incorporated herein by reference.
Item 13. Certain Relationships and Related Transactions
The Company has not engaged in any transaction or had any
relationship with any executive officer or director that is required
to be disclosed pursuant to Item 404 of Regulation S-K.
Part IV
Item 14. Exhibits, Financial Statement Schedule and Reports on Form
8-K
(a) The following documents are filed as part of this Annual Report
on Form 10-K:
1. Financial Statements.
The following Consolidated Financial Statements of Tripos,
Inc. and Reports of Independent Auditors are set forth in the
Company's 1996 Annual Report to Shareholders and are incorporated by
reference.
Annual Report
Page Number
Consolidated Balance Sheets as of
December 31, 1996 and 1995 . . . . . . . . . . . 18
Consolidated Statements of Operations
for each of the three years ended
December 31, 1996, 1995 and 1994 . . . . . . . . 19
Consolidated Statements of Cash Flows
for each of the three years ended
December 31, 1996, 1995 and 1994 . . . . . . . . 20
Consolidated Statements of Shareholders' Equity
for each of the three years ended December 31,
1996,1995 and 1994 . . . . . . . . . . . . . . 21
Notes to Consolidated Financial Statements . . . . .22 - 28
Report of Ernst & Young LLP, Independent Auditors
for the fiscal years ended December 31, 1996 and 1995 . 29
2. Financial Statement Schedule
The following financial statement schedule of Tripos, Inc.
is included in this annual report on
Form 10-K.
Page Number
Schedule II-Valuation and Qualifying Accounts II-1
Schedules other than that which is listed above have been
omitted since they are either not required, are not applicable, or
the required information is shown in the financial statements or
related items.
3. Exhibits - see the following Exhibit Index of this report.
The following exhibits listed in the Exhibit Index are filed
with this report:
10.12First Amendment to Lease between Tripos and Cahn Realty
Associates dated May 1, 1996
11 Statement Re: Computation of Per Share Earnings
13 The Registrant's 1996 Annual Report to Shareholders
(portions of which are incorporated by reference herein)
23.1 Consent of Ernst & Young LLP, Independent Auditors
27 Financial Data Schedule
(b) Reports on Form 8-K filed in the fourth quarter of 1996:
None.
(c) Exhibits - see Exhibit Index:
Management Contracts and Compensatory Plans - the following
exhibits listed in the Exhibit Index are listed below pursuant
to item 14(a)-3 of Form 10-K:
10.1 Tripos, Inc. 1994 Stock Option Plan
10.2 Tripos, Inc. 1994 Employee Stock Purchase Plan
10.3 Tripos, Inc. 1994 Director Option Plan
10.4 Tripos, Inc. 1994 401(k) Plan
10.5 Amendment to the 1994 401(k) Plan
10.6 Tripos, Inc. 1996 Director Stock Compensation Plan
Exhibit Exhibit Index
Number Description
2.1 Distribution Agreement between Tripos and E&S
3.1 Amended and Restated Articles of Incorporation
3.2 Amended and Restated Bylaws of Tripos
3.3 Amended and Restated Articles of Incorporation dated
January 26, 1996
10.1 Tripos, Inc. 1994 Stock Option Plan
10.2 Tripos, Inc. 1994 Employee Stock Purchase Plan
10.3 Tripos, Inc. 1994 Director Option Plan
10.4 Tripos, Inc. 1994 401(k) Plan
10.5 Amendment to the 1994 401(k) Plan
10.6 Tripos, Inc. 1996 Director Stock Compensation Plan
10.7 Master Collaboration Agreement between Tripos and MDL
Information Systems, Inc. dated February 2, 1996
10.8 Rights Agreement between Tripos and Boatmen's Trust Company,
as Rights Agent, dated January 26, 1996
10.9 Strategic Business Alliance Teaming Agreement between Tripos
and Panlabs, Inc. dated June 30, 1995
10.10 Credit Agreement-Line of Credit, dated as of September 12,
1996, between Tripos and Boatmen's National Bank of St. Louis
10.11 Lease between Tripos and Cahn Realty Associates dated July 11, 1995
10.12 First Amendment to Lease between Tripos and Cahn Realty
Associates dated May 1, 1996
11 Statement Re: Computation of Per Share Earnings
13 The Registrant's 1996 Annual Report to Shareholders
(portions of which are incorporated by reference herein)
21 Subsidiaries of the Registrant: Tripos S.A.R.L., Tripos UK
Limited and Tripos Associates, GMBH
23.1 Consent of Ernst & Young LLP, Independent Auditors
27 Financial Data Schedule
Previously filed as an exhibit to the Company's Registration
Statement on Form 10 dated May 27, 1994 and incorporated herein
by reference
Previously filed as an exhibit to the Company's Registration
Statement on Form S-8, 33-79610 dated May 31, 1994 and
incorporated herein by reference.
p Previously filed as an exhibit to the Company's Form 10-K
for the fiscal year ended December 31, 1995 and incorporated herein
by reference.
g Previously filed as an exhibit to the Company's Form 10-K
for the fiscal year ended December 31, 1994 and incorporated herein
by reference.
Previously filed as an exhibit to the Company's Form 10-Q for
the period ended September 30, 1996 and incorporated herein by
reference.
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the Registrant has duly caused this
report to be signed on its behalf by the undersigned, thereunto duly
authorized.
SIGNATURES
TRIPOS, INC.
By: John P. McAlister March 25, 1997
John P. McAlister, III Date
President, Chief Executive Officer and Member
of the Board of Directors
POWER OF ATTORNEY
Know all men by these presents, that each person whose signature
appears below constitutes and appoints John P. McAlister, III,
Colleen A. Martin and John D. Yingling, and each of them (with full
power to each of them to act alone), his true and lawful attorney-in-
fact and agent, with full power of substitution and resubstitution,
for him and in his name, place and stead, in any and all capacities,
to sign any or all amendments to this report on Form 10-K for the
fiscal year ended December 31, 1996, and to file the same, with all
exhibits thereto and other documents in connection therewith, with
the Securities and Exchange Commission, granting unto said attorneys-
in-fact and agents, and each of them, full power and authority to do
and perform each and every act and thing requisite and necessary to
be done in and about the premises, as fully to all intents and
purposes as he might or could do in person, hereby ratifying and
confirming all that said attorneys-in-fact and agents, or any of
them, or their substitutes, may lawfully do or cause to be done by
virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf
of the Registrant and in the capacities and on the dates indicated.
Name Title Date
John P. McAlister Chief Executive Officer, March 25, 1997
John P. McAlister III President and Director
(Principal Executive Officer)
Colleen A. Martin VP, Chief Financial March 25, 1997
Colleen A. Martin Officer and Secretary
(Principal Financial Officer)
John D. Yingling U.S. Controller and March 25, 1997
John D. Yingling Treasurer
(Principal Accounting Officer)
Ralph S. Lobdell Chairman of the Board of March 25, 1997
Ralph S. Lobdell Directors
Stewart Carrell Director March 25, 1997
Stewart Carrell
Gary Meredith Director March 25, 1997
Gary Meredith
Ferid Murad Director March 25, 1997
Ferid Murad
Alfred Alberts Director March 25, 1997
Alfred Alberts
TRIPOS, INC.
SCHEDULE II-VALUATION AND QUALIFYING ACCOUNTS
Years Ended December 31, 1994, December 31,1995 and December 31,
1996
(in thousands)
Col. A Col. B Col. C Col. D Col. E
Additions Deductions
Balance Charged Charged Charged Balance
at to Cost to to at End
Description Beginning and Other Reserves of
of Period Expenses Accounts Period
Allowance for
Doubtful Accounts
1994 $187 $(110) $-- $11 $66
1995 66 2 -- 28 40
1996 40 140 -- 103 77
Valuation Allowance for
Deferred Income Tax Assets:
1994 $-- $-- $-- $-- $--
1995 -- -- 434 -- 434
1996 434 -- -- 291 143
Exhibit 10.12
FIRST AMENDMENT TO LEASE
THIS FIRST AMENDMENT TO LEASE, made and entered into this 1st day
of May, 1996, by and between Cahn Realty Associates (hereinafter
referred to as "Landlord") and Tripos, Inc., a Utah corporation
(hereinafter referred to as "Tenant");
WITNESSETH:
WHEREAS, Landlord and Tenant entered into that certain Office
Building Lease, dated July 11, 1995 (hereinafter referred to as
"Lease"), for certain space known and numbered as Suite 303,
containing approximately 22,241 square feet of space and located at
1699 South Hanley Road, St. Louis, Missouri 63144 (hereinafter
referred to as the "Property"); and
WHEREAS, the primary term of said Lease commenced on July 1, 1995
and shall expire on August 31, 2000; and
WHEREAS, pursuant to Section 28 of said Lease, Tenant leased
additional space in the Property, containing approximately 1,980
square feet, thereby increasing the total space leased by Tenant to
approximately 24,221 square feet; and
WHEREAS, both Landlord and Tenant are desirous of amending said
Lease;
NOW THEREFORE, for and in consideration of the foregoing, and the
mutual covenants set forth below, it is agreed that said Lease is
hereby modified and amended as follows:
1. As of the Effective Date (as such term is hereinafter defined),
Tenant shall acquire and thereafter lease from Landlord two (2)
additional parcels of space within the Property, together containing
approximately 3,672 square feet, as more fully set forth on Exhibit
"A", attached hereto and made a part hereof (hereinafter
collectively referred to as "Additional Space").
As of the Effective Date, Tenant shall vacate and return to
Landlord a portion of the Original Space containing approximately
1,705 square feet, as more fully set forth on said Exhibit "A"
(hereinafter referred to as "Returned Space").
The result of Tenant leasing said Additional Space and releasing
said Returned Space is a net increase of square footage leased by
Tenant in the amount of approximately 1,967 square feet, thereby
increasing the total space leased by Tenant under said Lease to
approximately 26,188 square feet. Tenant shall lease the augmented
Premises upon the same terms and conditions as the Original Space,
except as set forth below.
2. Tenant has inspected the Additional Space and accepts the same
in its present "AS IS" condition; and, except as set forth below,
Tenant acknowledges that Landlord has made no representations to
Tenant with respect to any other alterations, repairs or
improvements to be performed by Landlord within such space.
Landlord, at Landlord's sole cost and expense, shall demolish a
portion of the temporary wall that was constructed within the
Premises in December 1995. The exact portion of the temporary wall
to be demolished shall be agreed upon between the parties. Landlord
shall also construct another wall within the Premises across for the
area designated for the receptionist. Landlord shall also assume
the obligation to remove all telecommunications wires utilized by
Landlord within said Additional Space. Tenant shall assume all
costs and obligations to relocate Tenant and all of Tenant's
personal property, equipment and telecommunications lines from the
Returned Space to the Additional Space.
When the work to be performed by Landlord has been substantially
completed (i.e., subject to normal "punchlist" items), Landlord
shall provide notice to Tenant, who shall then immediately inspect
the Premises and acknowledge in writing whether or not the work has
been performed according to this Amendment or any other plans and
specifications approved by the parties; provided, however, that
there shall be no withholding of acceptance if the work is
substantially completed such that there would be no material
interference with Tenant's use or occupancy of such space caused by
any incomplete work. It shall be deemed that Landlord has performed
all of its obligations with respect to such work unless Tenant give
Landlord written notice, within the first five (5) days after
delivery of such space, specifying in what respect Landlord has not
performed its obligations hereunder. If the work has been
substantially but not entirely completed, Tenant shall accept the
Additional Space and give Landlord a written punchlist of such items
necessary to complete; Landlord shall thereafter promptly complete
such items. Any disputes between Landlord and Tenant as to whether
or not the Additional Space or any punchlist has been substantially
completed, or with respect to any other matter related to any work
performed by Landlord within the Premises, shall be resolved by the
project general contractor.
Tenant acknowledges that the aforesaid work shall be performed
while Tenant is in possession of the Premises. Landlord shall use
good faith efforts to complete such work in such a manner as will
minimize any interference with the business of Tenant; nevertheless,
Landlord shall be the sole judge of the method and manner in which
such work shall proceed. In the event Tenant is inconvenienced by
Landlord's work, Tenant shall make no claim against Landlord, nor
shall any Rent payable to Landlord be reduced or abated while
Landlord is performing such work. However, Landlord shall remain
liable for any personal injuries suffered by Tenant or Tenant's
invitees directly caused by the negligence of Landlord while
Landlord is performing such work.
Landlord shall use good faith efforts to complete the aforesaid
interior finish work by May 1, 1996. However, in the event Landlord
shall be unable to deliver such work by such date, for any reason
including, but not limited to, labor strikes, casualty, legal
actions, suits or injunctions, condition of the elements, or the
inability to secure any materials, or in the event Tenant requests
any changes, modifications or additions to the aforesaid work to be
performed by Landlord, Landlord shall not be liable to Tenant, nor
shall the validity of this Amendment be impaired, but Landlord shall
cause such work to be completed as soon thereafter as possible.
Tenant shall have fourteen (14) business days from and after the
date Landlord delivers the Additional Space to Tenant in which to
vacate the Returned Space. During and for such fourteen (14) days,
Tenant shall remain liable for all rent and other charges accruing
under said Lease with respect to the Original Space (inclusive of
the Returned Space) and the Additional Space, plus all other costs
and damages sustained by Landlord as a result of Tenant's failure or
delay to vacate the Returned Space within said fourteen (14) days.
3. The parties acknowledge that, in connection with Tenant leasing
said Additional Space and releasing said Returned Space, a portion
of the Premises leased and/or used by Landlord, specifically the
area containing Landlord's computer mainframe, shall be inaccessible
to Landlord except through a path through the redefined Premises.
Therefore, notwithstanding anything to the contrary in this
Amendment or said Lease, Landlord hereby retains for itself, and
Tenant hereby grants to Landlord a twenty-four (24) hour easement
and right of access through the Premises for Landlord, and
Landlord's agents, employees and contractors for the purpose of
gaining access to and maintenance, repair and replacement of
Landlord's computer mainframe. Landlord shall use good faith
efforts not to unreasonably interfere with Tenant's use of the
Premises during or in connection with Landlord's use of such
easement; Landlord shall be liable for any direct damages to
property or injuries to persons proximately caused by Landlord's
entry or use of such easement. Tenant acknowledges that the
aforesaid easement, and Landlord's unrestricted right to gain access
to Landlord's computer mainframe, is material consideration for the
execution of this Amendment. The twenty-four (24) hour easement and
right of access is not assignable, except and only in the event such
assignment/sublease is to an affiliated company of Landlord who
occupies Landlord's premises within the Property. At such time as
Landlord no longer requires the area containing its computer
mainframe or access to the area (including a reasonable time to
remove such mainframe), said easement and Landlord's right of access
shall terminate and said area shall instantly become available to
Tenant. In the event Tenant denies or material delays Landlord's
access in and across such easement to Landlord's computer mainframe,
Tenant shall be in default under said Lease, and Tenant shall be
liable for all damages sustained by Landlord. In addition, Landlord
shall have the right to seek immediate relief, or other equitable
remedies, to enforce this provision.
4. As of the Effective Date, Tenant shall pay to Landlord, as Base
Rent for the entire Premises, the amount set forth below.
Original Space Additional Total Total
Monthly Base Monthly Base Monthly Annual
Period Rent Rent Base Rent Base Rent
Effective Date through
August 31, 2000
$33,808.50 $2,745.60 $36,554.10 $438,649.20
Payment shall be made on the first day of each calendar month, in
advance, without set off or deduction, at the office of Landlord.
In the event the Effective Date is any date other than the first day
of a calendar month, the rent payable for such partial month shall
be equitable pro rated to reflect such adjusted rent.
5. For purposes of this Amendment, the Effective Date shall
be defined as the date Landlord tenders to Tenant the Additional
Space with all work therein to be performed by Landlord
substantially completed. In the event Landlord delivers the
Additional Space to Tenant on any date other than May 1, 1996,
Landlord and Tenant shall execute Landlord's written memorandum,
setting forth the actual delivery date, the date when all rent shall
be adjusted, and any punchlist items which Landlord must complete,
and any other information reasonably requested by Landlord.
6. Landlord and Tenant each warrant that they have dealt with
no broker or other person claiming a commission for or in connection
with this First Amendment to Lease; and each party shall hold the
other harmless for any breach of such warranty.
7. Tenant acknowledges that Landlord has complied with all
alterations, additions, and replacements under said Lease with
respect to the Premises, and that the Premises are not in need of
repair or maintenance; and Tenant hereby ratifies acceptance of the
Premises in its present "AS IS" condition.
Except as hereby amended, all other terms and conditions of said
Lease shall remain unchanged, and shall be in full force and effect
as if again recited herein.
WHEREFORE, the parties have executed this First Amendment to
Lease the day and year first above written.
LANDLORD: TENANT:
CAHN REALTY ASSOCIATES TRIPOS, INC.
a Utah corporation
By: Paul Cahn By: John P. McAlister
Print Name:Paul Cahn Print Name: John P. McAlister
Title: Landlord Title: President & CEO
Exhibit 11
Statement Re: Computation of Per Share Earnings
For the years ended December 31, 1996, 1995 and 1994
(In thousands, except per share data)
Year Ended
1996 1995 1994
Primary:
Average shares 2,923,284 2,859,533 -
outstanding
Net effect of options 295,219 - -
3,218,503 2,859,533 -
Net income (loss) $1,952 $(1,696) $352
Per share amount $0.61 $(0.59) -
Fully diluted:
Average shares 2,923,284 - -
outstanding
Net effect of options 365,547 - -
3,288,831 - -
Net income (loss) $1,952 $(1,696) $352
Per share amount $0.59 - -
Exhibit 13
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read in conjunction with the audited
consolidated financial statements and notes thereto for the year ended
December 31, 1996.
Overview
Tripos, Inc. is a discovery research company with unique expertise
in molecular informatics. Tripos supplies software, research services,
and compound libraries to the pharmaceutical, biotechnology and other
life science industries worldwide.
Except for the historical information and statements contained in
Management's Discussion and Analysis of Financial Condition and Results
of Operations ("MD&A"), the matters and items contained in this
document, including MD&A, contain certain forward-looking statements
that involve uncertainties and risks, some of which are discussed
below, including under the caption "Cautionary Statements-Additional
Important Factors to Be Considered".
The Company's revenues and expenses can vary from quarter to
quarter depending upon, among other things, the capital expenditure
budgets of its customers, lengthy sales cycles, market acceptance of
new products and enhanced versions of existing products, the timing of
new product introductions by the Company and other vendors, changes in
pricing policies by the Company and other vendors, and changes in
general economic and competitive conditions. In addition, a
substantial portion of the Company's revenues for each quarter is
attributable to a limited number of orders and tends to be realized
toward the end of each quarter. Thus, even short delays or deferrals
of sales near the end of a quarter can cause quarterly results to
fluctuate substantially. The Company typically experiences greater
gross margins on software licenses, contract research, and compound
sales than on sales of hardware. The Company's profitability depends
in part on the mix of its revenue components and not necessarily on
total revenues.
Effective June 1, 1994, the former parent of the Company, Evans
and Sutherland Computer Company ("E&S"), distributed all outstanding
shares of the common stock of the Company (formerly Tripos Associates,
Inc.) to E&S shareholders (the "Distribution") such that every three
shares of E&S yielded one share of the Company. Shortly before the
Distribution, the Company changed its name to Tripos, Inc.
Immediately prior to the Distribution, E&S transferred to
additional paid-in-capital the CompanyOs intercompany debt owed to E&S
of $6,421,380, made a cash contribution to the Company of $6,506,248,
compensated the Company for a $403,000 tax benefit related to net
losses incurred by the Company during the period from January 1, 1994
to May 31, 1994, and transferred to the Company the E&S European
operations related to the Company.
Results of Operations
The following table sets forth, for the periods indicated, certain
consolidated financial data as a percentage of net sales (except cost
of sales data, which is set forth as a percentage of the corresponding
net sales data):
1996 1995 1994
Net sales:
Software licenses 32% 41% 45%
Support 32 31 28
Accelerated discovery services 23 10 -
Hardware 13 18 27
Total net sales 100 100 100
Cost of sales:
Software licenses 19 19 17
Support 5 3 4
Accelerated discovery services 49 56 -
Hardware 92 89 91
Total cost of sales 35 31 33
Gross profit 65 69 67
Operating expenses:
Sales and marketing 37 47 42
Research and development 12 17 17
General and administrative 8 7 6
Restructuring charge - 10 -
Total operating expenses 57 81 65
Income (loss) from operations 8 (12) 2
Other income, net 1 2 1
Net income (loss) before income taxes 9 (10) 3
Income tax expense (benefit) 2 (2) 1
Net income (loss) 7 (8) 2
Net Sales Net sales increased approximately 8% from $19.6 million in
1994 to $21.1 million in 1995 and increased 36% in 1996 to $28.8
million. These increases in net sales were principally attributable to
sales of diverse chemical compound libraries in the Accelerated
Discovery Services ("ADS") business. These increases were augmented by
increases in software and support sales. New product sales represented
24% of software license sales in 1994, 14% in 1995, and 11% in 1996.
The Company sells its software products directly in North America,
through its wholly owned subsidiaries in Europe, through an exclusive
distributor arrangement in Japan, and through nonexclusive agency
relationships in China, India, Korea, Singapore and Taiwan. Net sales
from the Company's activities outside of North America represented
approximately 57%, 49% and 48% of the Company's total net sales in
1994, 1995 and 1996, respectively. Net sales in Europe accounted for
48%, 39%, and 38% of the Company's net sales in 1994, 1995, and 1996,
respectively, with the balance from customers in the Pacific Rim area,
principally Japan. The Company believes that revenues from its foreign
activities will continue to account for a significant percentage of its
total net sales.
Tripos generates a substantial portion of its revenues from the
pharmaceutical industry. Net sales to this industry accounted for
approximately 69%, 58%, and 58% of the Company's total net sales in
1994, 1995, and 1996, respectively.
List prices for the Company's products have remained relatively
stable over the last few years. Prices set by the Company for initial
purchases of the Company's software products, including modules, are
typically significantly higher than the prices for follow-on customer
purchases. As a result, the average software license revenue per
customer order has declined as the Company's current installed base has
purchased additional simultaneous user licenses for previously
purchased software. The sale price for the chemical compound libraries
has increased slightly as a result of the increase in the size and
number of the orders in 1996 versus 1995, when the product was
introduced. In 1996, existing customers represented 87% of total net
sales. Increasing net sales from period to period is dependent, in
part, on the Company's ability to introduce new products which are
accepted by the market and on the Company's ability to penetrate new
and existing markets.
Software license sales decreased 2% from $8.8 million in 1994 to
$8.7 million in 1995 and increased 6% to $9.2 million in 1996. The
decrease in 1995 is attributable to the lengthy customer decision
cycles on new combinatorial chemistry products and concentrated selling
efforts in the now discontinued Unison product line. In 1996, the
growth in software sales is due to the increase in orders of worldwide
licenses for the large pharmaceutical companies and the increased
penetration into the biotechnology sector.
Support sales increased 16% from $5.6 million in 1994 to $6.5
million in 1995 and increased 3% to $6.7 million in 1996. The increase
in 1995 is primarily due to a larger installed base of customers with
more modules per customer as a result of the overall increase in
software license sales in the prior years. The decline in 1996 in the
percentage increase in support sales is due to the consolidation of
customer support sites for worldwide licenses.
The Company introduced the Accelerated Discovery Services ("ADS")
product line in September 1995 through an alliance with Panlabs, Inc.
The sales of diverse compound libraries and contract research generated
totals of $2.1 million in 1995 and $9.1 million in 1996, an increase of
329%. The increase in compound library revenue from $2.1 million in
1995 to $8.2 million in 1996 is due to the increase in the number of
compounds available for sale, from 40,000 to 80,000. Also, the Company
now has extended its sales staff for wider distribution of this
relatively new product line. The number of compounds available for
sale will increase throughout 1997. The Company sold compound
libraries to 50 customers to date. The ADS business also recognized
revenue on several research contracts in 1996 and plans to increase
this revenue stream in 1997.
Hardware revenues decreased 26% to $3.8 million in 1995 from $5.2
million in 1994. In 1996, hardware sales were constant at $3.8 million.
The decline in 1995 and the constant dollar amount in 1996 reflect the
Company's strategy of deemphasizing low-margin hardware sales.
Cost of Sales Total cost of sales increased 1% from $6.4 million in
1994 to $6.5 million in 1995 and increased 55% to $10 million in 1996,
which represents 33%, 31% and 35%, respectively, of total net sales.
In 1995, royalty costs paid to third-party developers increased as the
mix of software license revenue changed; added to the costs of the
diverse compound libraries, these increases offset the decline in
hardware costs for the year. The cost of the diverse compound libraries
was the principal factor in the overall increase in cost of sales in
1996.
Costs of software licenses represented 17%, 19% and 19% of
software license sales in 1994, 1995, and 1996, respectively. Costs of
software licenses consist of amortization of capitalized software,
royalties to third-party developers, and the cost of software product
packaging and media. In 1995 and 1996, the cost of software licenses
as a percentage of software license sales increased as the Company
introduced new software products requiring significant increases in
product documentation, broad-based distribution, and royalty payments.
Costs of support represented 4%, 3% and 5% of support sales in
1994, 1995, and 1996, respectively. Cost of support principally
consists of software product packaging, media and updates to
documentation. In 1995, the decrease in costs of sales of support is
based on relatively fixed production costs of the manuals and media for
software updates. The increase in costs of sales for support in 1996
is based on the shipment of a major release of software to a base of
over 700 customers.
Costs of ADS represented 56% in 1995 and 49% in 1996 of ADS
sales. Costs of ADS represent the cost associated with the design and
creation of the diverse compound libraries. The decrease in the costs
of ADS as a percentage of sales is due to the increase of higher margin
contract research revenues. The Company expects the costs of this
product line to decline slightly as a percentage of sales in the future
as contract research revenues become a higher percentage of the product
mix.
Costs of hardware represented 91%, 89% and 92% of hardware sales
in 1994, 1995 and 1996, respectively. Costs of hardware consist
primarily of the costs of hardware sold. The Company expects the cost
of hardware as a percentage of hardware sales to remain relatively
stable in future periods.
Gross Profit Gross profit was $13.2 million in 1994, $14.6 million in
1995, and $18.8 million in 1996, which represents gross profits of 67%,
69% and 65%, respectively. The decrease in the 1996 gross profit
percentage was due to the increase in compound library sales which have
higher cost of sales than software and support. The Company believes
that gross profit will remain comparable or improve slightly as higher
margin contract research and software license revenues increase.
Sales and Marketing Expenses Sales and marketing expenses increased
21% from $8.3 million in 1994 to $10.0 million in 1995, and increased
8% to $10.7 million in 1996. This increase was primarily due to the
expansion of the sales and marketing organization in Europe for the
sale of the ADS product line, the creation of a business development
and strategic relations department, and increases in marketing and
selling of new products. Sales and marketing expenses as a percentage
of net sales increased from 42% in 1994 to 47% in 1995, and decreased
to 37% in 1996. The decrease in sales and marketing expenses as a
percentage of sales in 1996 is a function of increased sales along with
improved efficiencies among the sales and marketing staff. The Company
expects total sales and marketing expenses as a percentage of net sales
to decline slightly in the future as cost efficiencies continue to be
implemented in the worldwide sales and marketing staff.
Research and Development Expenses Research and development expenses
increased 3% from $3.4 million in 1994 to $3.6 million in 1995, and
decreased 5% to $3.4 million in 1996, representing 17%, 17%, and 12% of
net sales, respectively. This decrease was primarily due to the
reduction in development staff resulting from the discontinuation of
the Unison product in December 1995.
Research and development expenses, including the amount of
capitalized costs, were $4.3 million in 1994, $6.8 million in 1995 and
$7.0 million in 1996, which represents 22%, 32%, and 24% of net sales,
respectively. In accordance with Statement of Financial Accounting
Standards No. 86, the Company capitalized $.9 million in 1994 of
software development and $3.2 million and $3.6 million in costs of
software development and compound library creation and design in 1995
and 1996, respectively. This represented 21%, 47% and 51% of total
product research and development expenditures in these periods. The
Company anticipates that its investment in new product research will
remain at comparable levels as Tripos continues development in web-
based tools, desktop applications, diverse compound libraries, and
combinatorial chemistry tools.
General and Administrative Expenses General and administrative
expenses increased 20% from $1.2 million in 1994 to $1.4 million in
1995, and increased 66% to $2.4 million in 1996, representing 6%, 7%,
and 8% of net sales, respectively. The increase in expenses is the
result of an increase in the bad debt provision, increased shareholder
relations activities and funding the Company's incentive bonus pool for
exceeding operating income goals. The Company expects general and
administrative expenses to remain at comparable levels in the future.
Restructuring Charge The company incurred a nonrecurring restructuring
charge of approximately $2.2 million in the fourth quarter of 1995
related to the discontinuation of development, marketing and sales of
the Unison product line. The Company discontinued this line in
conjunction with an alliance which was formed with its major competitor
in the market where this product was sold. This alliance allowed the
Company to reallocate certain resources to the continued development of
other product lines. The charge represented the write-off of previously
capitalized development costs, write-down of assets used in product
development, settlement of contractual obligations, and severance
costs.
All cash outlays related to the restructuring for severance costs
and settlement of contractual obligations have been paid out as of
December 31, 1996. The amount reserved for these cash outlays was
estimated at $447,000 and occurred principally in the first quarter of
1996. The source of funding was cash generated from operations. The
remaining components of the restructuring charge represented the write-
down of previously capitalized development costs of $1.6 million and
the write-off of equipment used in the development of the product of
$110,000.
The effects of the restructuring plan on operating results for
1996 were realized through reduced annual amortization charges of
$139,000 and reduced labor costs of $350,000. The anticipated effects
for 1997 will be reduced amortization costs of $139,000 and reduced
labor costs of $350,000. The impact on annual revenues in 1996 and for
1997 are considered minimal as the Unison product contributed less than
5% of software license sales in 1995.
Interest Income Interest income of $247,000 in 1994, $424,000 in 1995
and $425,000 in 1996, was from interest earned on investments.
Other Income The Company had other income (expense) of $(19,000) in
1994, $25,000 in 1995 and $(17,000) in 1996.
Income Tax Expense The Company's tax expense (benefit) was $186,000 in
1994, $(339,000) in 1995 and $760,000 in 1996. The Company's effective
tax rate was 35%, 17% and 28% for 1994, 1995 and 1996, respectively.
Prior to the date of the Distribution, the Company was included in the
consolidated income tax return of E&S. The effective rates for 1995
and 1996 reflect the impact of net operating loss carryforwards for
which current benefits were not recognized until the second quarter of
1996.
Liquidity and Capital Resources
The Company's working capital increased from $8.6 million in 1995
to $10.4 million in 1996. The increase in working capital is the
result of the Company's earnings for the current year.
Net cash provided by operating activities increased from $1.9
million in 1995 to $4.9 million in 1996. This primarily was due to a
change in net income of $3.6 million and an increase in amortization of
$1.1 million, offset by the restructuring charge taken in the previous
year.
Net cash used in investing activities increased from $.2 million
in 1995 to $4.5 million in 1996. The increase relates to net purchases
of investments throughout the year. The Company invests available cash
in bank deposits, investment-grade securities and, short-term interest-
producing investments, including government obligations and other money
market instruments. The level of 1996 capital expenditures is 8% over
the prior year. The Company anticipates that 1997 capital purchases
will be comparable to 1996.
Net cash provided by financing activities increased from $.1
million in 1995 to $1.0 million in 1996 as the result of stock issued
pursuant to stock plans.
Management believes that with the current cash position of $5.4
million, short-term investments of $3.3 million, accounts receivable of
$10.6 million, continued cash flow from operations, availability of a
$2.5 million line-of-credit, and total current liabilities of $9.5
million, the Company will be able to meet both its liquidity needs and
capital expenditure needs for the next 12 months. Management believes
that with total long-term liabilities of $.6 million and no other known
long-term commitments or demands, the Company will be able to satisfy
its known long-term liabilities and liquidity needs through the funding
sources identified above.
Foreign Currency Translations
The Company's foreign operations transact the majority of their
business in their respective local currencies and are therefore
generally not exposed to foreign currency gains or losses. Due to the
relative stability of the currency of the countries in which the
Company operates and the level of investment in each country, the
Company's current intent is to retain assets within its foreign
operations to fund those operations. The Company's foreign currency
transaction gains and losses have not been significant to date, and
management believes the Company's exposure to future foreign currency
transaction gains and losses is minimal.
Cautionary Statements-Additional Important Factors to Be Considered
The Company's future results could differ materially from those
discussed in this document. Factors that could contribute to such
differences, include, but are not limited to, the following:
Rapid Technological Change. The software and discovery research
industries are characterized by rapid change and uncertainty due to new
and emerging technologies. The pace of change has recently accelerated
due to the Internet, combinatorial chemistry software products, and
combinatorial chemistry companies entering the market. There can be no
assurance that Tripos will be successful in developing or acquiring
product enhancements and new products necessary to keep pace with the
changing technologies.
Customer Acceptance. While the Company provides a database of the
chemical compounds in its library and performs extensive usability and
beta-testing of its new software products, user acceptance and
corporate penetration rates ultimately dictate the success of
development and marketing efforts.
Competition. The discovery research industry is highly
competitive. A number of companies offer products that target the
discovery research market. Tripos competes with software and discovery
research vendors for the research budgets of pharmaceutical and
biotechnology companies. Certain of the Company's competitors have
substantially greater financial, technical, marketing and sales
resources than Tripos.
Dependence on Key Personnel. Tripos' continued success depends to
a significant degree upon the continued service of its President and
CEO, John P. McAlister, and other key technical and senior management
personnel. The loss of the services of Dr. McAlister or any other key
personnel and the inability of the Company to attract and retain
suitable replacements could have a material adverse effect on the
Company.
Possible Acquisitions. The Company may make acquisitions in the
future. Acquisitions involve numerous risks, including difficulties in
the assimilation of the operations and products of the acquired
companies, the diversion of management's attention from other business
concerns, risks of entering markets in which the Company has little or
no direct experience, and potential loss of key employees of the
acquired companies.
Consolidated Balance Sheets
Year ended Year ended
December 31, December 31,
1996 1995
Assets:
Current assets:
Cash and cash equivalents................ $5,393,074 $3,954,804
Investments.............................. 3,335,444 3,178,637
Accounts receivable, less allowance for
doubtful accounts of $77,381 in 1996
and $40,419 in 1995.................... 10,557,620 7,357,324
Prepaid expenses.......................... 495,571 469,406
Deferred income taxes.................... 118,000 610,000
Total current assets.................. 19,899,709 15,570,171
Property and equipment, less accumulated
depreciation........................... 1,163,645 1,191,386
Capitalized development costs, net of
accumulated amortization of $4,945,567
in 1996 and $2,460,670 in 1995........... 3,130,013 2,264,394
Other, net................................... 315,667 33,100
Total assets.......................... 24,509,034 19,059,051
Liabilities and shareholders' equity:
Current liabilities:
Accounts payable......................... 844,920 1,120,136
Accrued expenses.......................... 5,305,603 2,489,596
Deferred revenue.......................... 3,389,129 3,321,964
Total current liabilities............. 9,539,652 6,931,696
Deferred income taxes....................... 602,000 805,000
Shareholders' equity
Common stock, $.01 par value; authorized
20,000,000 shares; issued and outstanding
3,012,052 shares in 1996 and 2,879,763
shares in 1995........................... 30,121 28,798
Additional paid-in capital............... 15,219,679 14,236,705
Retained earnings (deficit)............. (1,381,501) (3,333,717)
Cumulative translation adjustment........ 499,083 390,569
Total shareholders' equity .......... 14,367,382 11,322,355
Total liabilities and shareholders' equity.. $24,509,034 $19,059,051
See notes to consolidated financial statements
Consolidated Statements of Operations
Year ended Year ended Year ended
December 31, December 31, December 31,
1996 1995 1994
Net sales:
Software licenses.............. $9,185,917 $8,650,772 $8,848,060
Support........................ 6,715,669 6,510,213 5,563,628
Accelerated discovery services. 9,053,042 2,111,518 -
Hardware....................... 3,831,765 3,825,035 5,189,909
Total net sales................ 28,786,393 21,097,538 19,601,597
Cost of sales:
Software licenses.............. 1,735,380 1,664,070 1,477,210
Support........................ 305,000 214,088 224,880
Accelerated discovery services. 4,422,477 1,181,995 -
Hardware....................... 3,527,871 3,398,023 4,713,445
Total cost of sales............ 9,990,728 6,458,176 6,415,535
Gross profit...................... 18,795,665 14,639,362 13,186,062
Operating expenses:
Sales and marketing............ 10,704,959 9,951,160 8,259,000
Research and development....... 3,387,500 3,559,320 3,409,387
General and administrative,
including allocations from
former parent of approximately
$111,000 in 1994............. 2,399,003 1,449,108 1,207,883
Restructuring charge........... - 2,164,463 -
Total operating expenses....... 16,491,462 17,124,051 12,876,270
Income (loss) from operations..... 2,304,203 (2,484,689) 309,792
Interest income ................. 424,826 424,253 246,647
Other income (expense), net....... (16,813) 25,282 (18,932)
Income (loss) before income taxes. 2,712,216 (2,035,154) 537,507
Income tax expense (benefit)...... 760,000 (339,431) 185,787
Net income (loss)................. 1,952,216 (1,695,723) 351,720
Primary earnings (loss) per share. $0.61 $(0.59)
Primary weighted average number of
shares.......................... 3,218,503 2,859,533
Fully diluted earnings per share.. $0.59 -
Fully diluted weighted average
number of shares.............. 3,288,831 -
See notes to consolidated financial statements
Consolidated Statements of Cash Flows
Year ended Year ended Year ended
December 31, December 31, December 31,
1996 1995 1994
Operating activities:
Net income (loss)................ $1,952,216 $(1,695,723) $351,720
Adjustments to reconcile net income (loss) to
net cash provided by operating activities:
Depreciation of property and
equipment....................... 790,190 1,017,075 819,895
Amortization of capitalized
development costs............... 2,484,897 1,404,739 587,023
Deferred income taxes............ 289,000 (446,431) 216,431
Net (gain) loss from sale of
property, plant & equipment...... (25,264) 18,292 -
Noncash restructuring charge..... - 1,717,722 -
Change in operating assets and liabilities:
Accounts receivable.............. (3,055,248) 295,518 433,158
Prepaid expenses and other assets (1,022) 374,065 (578,625)
Accounts payable and accrued
expenses........................ 2,449,341 (910,232) 1,239,287
Deferred revenue................. 25,826 171,013 516,395
Net cash provided by operating
activities........................ 4,909,936 1,946,038 3,585,284
Investing activities:
Purchases of investments......... (2,465,000) (3,178,637) (20,627,106)
Sales and maturities of
investments......... .... ..... 2,308,193 6,855,373 13,771,733
Purchases of property and
equipment........................ (734,604) (680,916) (582,800)
Capitalized development costs... (3,618,796) (3,176,884) (906,395)
Net cash used in investing
activities........................ (4,510,207) (181,064) (8,344,568)
Financing activities:
Stock issuance pursuant to stock
plans............................ 984,297 128,974 46,265
Capital contributions provided
by former parent................. - - 146,317
Due to former parent, net change. - - (110,500)
Cash contribution by former
parent........................... - - 6,506,248
Net cash provided by financing
activities........................ 984,297 128,974 6,588,330
Effect of foreign exchange rate
changes on cash and cash
equivalents.. ................. 54,244 128,944 40,462
Net increase in cash and cash
equivalents............... ..... 1,438,270 2,022,892 1,869,508
Cash and cash equivalents at
beginning of year................ 3,954,804 1,931,912 62,404
Cash and cash equivalents at end
of year.......................... $5,393,074 $3,954,804 $1,931,912
Supplemental disclosure of noncash financing and investing activities:
Transfer of intercompany debt by
former parent to additional paid-in
capital.. ...................... $ - $ - $6,421,380
See notes to consolidated financial statements
Consolidated Statements of Shareholders' Equity
<TABLE>
<CAPTION> Total
Share
Common Stock Additional Retained Foreign holders'
Paid-in Earnings Currency Equity
Shares Amount Capital (Deficit) Translation (Deficit)
<S> <C> <C> <C> <C> <C> <C> n
Balance at December 31,
1993................ 1,000 $31,461 $1,379,247 $(1,989,714) $288,842 $(290,164)
Retirement of original
issue................. (1,000) (31,461) 3,011 - - (28,450)
Stock issued pursuant
to the Distribution... 2,845,000 28,450 - - - 28,450
Stock issued under
stock purchase plan... 9,740 97 46,168 - - 46,265
Return of capital to
former parent......... - - (248,072) - - (248,072)
Cash contribution by
former parent......... - - 6,506,248 - - 6,506,248
Transfer of inter-
company debt by former
parent to additional
paid-in capital...... - - 6,421,380 - - 6,421,380
Translation adjustment - - - - 40,462 40,462
Net income........... - - - 351,720 - 351,720
Balance at December 31,
1994............... 2,854,740 28,547 14,107,982 (1,637,994) 329,304 12,827,839
Stock issued under
stock purchase plan... 21,890 220 111,082 - - 111,302
Stock issued under
stock option plan.... 3,133 31 17,641 - - 17,672
Translation adjustment - - - - 61,265 61,265
Net loss.............. - - - (1,695,723) - (1,695,723)
Balance at December 31,
1995................. 2,879,763 28,798 14,236,705 (3,333,717) 390,569 11,322,355
Stock issued under
stock purchase plan... 32,602 326 164,435 - - 164,761
Stock issued under
stock option plan..... 98,264 983 801,803 - - 802,786
Stock issued under
director compensation
plan................ 1,423 14 16,736 - - 16,750
Translation adjustment - - - - 108,514 108,514
Net income............ - - - 1,952,216 - 1,952,216
Balance at December 31,
1996............ 3,012,052 $30,121 $15,219,679 $(1,381,501) $499,083 $14,367,382
</TABLE>
See notes to consolidated financial statements
Notes to Consolidated Financial Statements December 31, 1996
1. Description of Business and Summary of Significant Accounting
Policies
Description of Business and Company Organization Tripos, Inc.
delivers science, tools and analysis services that advance
customers' creativity and productivity in pharmaceutical,
agrochemical, biotechnology and related research industries
worldwide. The Company is also a value-added reseller of third-
party hardware products required to operate its software products.
A substantial portion of the Company's business is conducted with
pharmaceutical companies, however, the Company is not economically
dependent on any customer on an ongoing basis.
Effective June 1, 1994, Evans and Sutherland Computer Company
(OE&SO), the former parent of the Company, distributed all
outstanding shares of the common stock of the Company (formerly
Tripos Associates, Inc.) to E&S shareholders (Othe DistributionO)
such that every three shares of E&S yielded one share of the
Company. Shortly before the Distribution, the Company changed its
name to Tripos, Inc.
Immediately prior to the Distribution, E&S tranferred to
additional paid-in capital the Company's intercompany debt owed to
E&S totaling $6,421,380, made a cash contribution to the Company of
$6,506,248, compensated the Company for a $403,000 tax benefit
related to net losses incurred by the Company during the period from
January 1, 1994 to May 31, 1994, and transferred to the Company the
E&S European operations related to the Company.
Basis of Presentation The accompanying consolidated financial
statements include the accounts of the Company and its wholly owned
subsidiaries. All significant intercompany accounts and
transactions are eliminated in consolidation. For all periods prior
to June 1, 1994, the accompanying consolidated financial statements
include the historical assets, liabilities, revenues and expenses
directly related to the Company's operations. Included in general
and administrative expenses are allocations from E&S, determined
using a formula based on revenues, payroll, property and equipment,
and inventory. The allocations of expense are reasonable in the
opinion of management. The financial information for the periods
prior to June 1, 1994, included herein may not necessarily be
indicative of the financial position, results of operations or cash
flows of the Company in the future or what the balance sheets,
statements of operations or cash flows of the Company would have
been if it had been a separate, stand-alone company during the
entirety of the periods presented.
On July 27, 1994, the Company adopted reporting periods with a
December 31 calendar year end. Previously, the Company used 52 or
53 week periods which ended on the last Friday of December. The
effect of changing the fiscal year end was immaterial.
Cash and Cash Equivalents All highly liquid investments with a
maturity of three months or less when purchased are considered to be
cash equivalents.
Investments In May 1993, the Financial Accounting Standards Board
issued Statement of Financial Accounting Standards No. 115 ("SFAS
115"), "Accounting for Certain Investments in Debt and Equity
Securities." The Company adopted the provisions of the new standard
for investments held as of or acquired after January 1, 1994. In
accordance with the Statement, prior period financial statements
have not been restated to reflect the change in accounting
principle. There was no cumulative effect from adopting SFAS 115 on
January 1, 1994, since the Company held no investment securities at
that date.
The Company's investments, which consist primarily of U.S.
government and other high-quality debt securities with maturities of
less than five years, have been classified as available-for-sale and
are carried at fair value. There were no unrealized holding gains
and losses since the fair value approximated the amortized cost of
investments at each year-end. .
Property and Equipment Property and equipment are stated at cost.
Depreciation is computed by applying an accelerated method over the
estimated useful lives of the assets, which range from five to ten
years for equipment and furniture, the shorter of the useful life of
the improvement or the life of the related lease for leasehold
improvements, and three years for purchased software.
Development Costs Development costs consist of software
development costs which are capitalized after the establishment of
technological feasibility in accordance with Statement of Financial
Accounting Standards No. 86 and costs associated with the design and
creation of diverse compound libraries related to the Company's
Accelerated Discovery Services. Amortization of capitalized
software development costs is provided on a product-by-product basis
as the greater of (a) the ratio of current gross revenues for a
product to the total current and anticipated future gross revenues
or (b) the straight-line method over the remaining estimated
economic life of the product. Currently, the Company is using an
estimated economic life of three to five years. Prior to 1994, the
Company used an estimated economic life of three years. Capitalized
costs associated with the diverse compound libraries are amortized
on a two year straight-line basis.
The Company assesses the recoverability of capitalized
development costs by comparing the remaining unamortized balance to
the net realizable value of the related product. Any excess is
written off. All other research and development expenditures are
charged to research and development expense in the period incurred.
Revenue Recognition The Company recognizes revenue from software
licenses and chemical compound sales upon product delivery, customer
acceptance with all obligations fulfilled at the date of delivery,
and determination that collectibility of the sale proceeds is
probable. The Company recognizes revenue from software support
contracts ratably over the term of the contract, typically one year.
Hardware sales are recognized on delivery of the product from the
CompanyOs vendor to the CompanyOs customer.
The Company has entered into contract research agreements and
consulting arrangements with certain customers which provide for
collaboration with the Company in defining related software
products, early access to the products, discounts on licenses for
the products developed and compound library design. The Company
recognizes revenue related to contract research and consulting
agreements as contractual milestones are achieved and delivered or,
absent such contractual milestones, on a completed contract basis.
Warranty The Company is a reseller of hardware and passes through
to its customers the standard warranties provided by the hardware
supplier. The Company warrants its application software products to
perform in accordance with written user documentation and the
agreements negotiated with the customer. Since the Company does not
customize its applications software, software warranty costs are
insignificant and expensed as incurred.
Foreign Currency Translation The local foreign currency is the
functional currency for the Company's foreign operations. Assets
and liabilities of foreign operations are translated to U.S. dollars
at the current exchange rates as of the applicable balance sheet
date. Revenues and expenses are translated at the average exchange
rates prevailing during the period. Adjustments resulting from
translation are reported as a separate component of shareholders'
equity. Net gains and losses from foreign currency transactions
were not significant during any of the years presented.
Income Taxes The provision for income taxes is computed using the
liability method. The primary difference between financial
statement and taxable income results from the use of different
methods of computing depreciation, capitalized development costs,
accrued vacation and customer deposits.
Earnings Per Common and Common Equivalent Share Earnings per
common and common equivalent share for 1996 were computed using the
weighted average number of common shares and common equivalent
shares outstanding during the year. Common stock equivalents
consist of outstanding stock options. Loss per share for 1995 and
the first quarter of 1996 was computed using the weighted average
number of common shares outstanding during the period and did not
include common equivalent shares as their inclusion would have
resulted in an anti-dilutive effect. Fully diluted loss per share
was not reported for 1995 because it would have been anti-dilutive.
Earnings per common and common equivalent share have not been
presented for 1994 in the accompanying consolidated statements of
operations because prior to June 1, 1994, the Company consisted of
separate subsidiaries and divisions of E&S and had no separately
issued equity securities.
Stock Option Plans The Company has elected to follow Accounting
Principles Board Opinion No. 25 ("APB 25"), "Accounting for Stock
Issued to Employees", and related Interpretations in accounting for
its employee stock options. Under APB 25, because the exercise
price of the Company's employee stock options equals the market
price of the underlying stock on the date of grant, no compensation
expense is recognized. The Financial Accounting Standards Board has
issued SFAS 123, "Accounting and Disclosure of Stock-Based
Compensation", effective for years beginning after December 1994.
The Company has elected to disclose the effects of this
pronouncement in a footnote to these financial statements. (See
Note 6)
Accounting Estimates The preparation of financial statements in
conformity with generally accepted accounting principles requires
management to make estimates and assumptions that affect the
reported amounts of assets, liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and
the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.
2. Property and Equipment
Property and equipment at the end of each year are summarized
below:
1996 1995
Computer equipment......... $3,843,216 $3,345,965
Furniture and fixtures...... 1,599,154 1,470,946
Purchased software......... 988,770 909,827
6,431,140 5,726,738
Less accumulated
depreciation 5,267,495 4,535,352
$1,163,645 $1,191,386
3. Accrued Expenses
Accrued expenses consist of the following at the end of each
year:
1996 1995
Payroll related.............. $1,323,800 $220,817
Income taxes payable......... (145,413) 22,259
Restructuring charge......... - 446,740
Compound development.......... 3,047,212 955,390
Other..................... 1,080,004 844,390
$5,305,603 $2,489,596
4. Restructuring Charge
The Company took a charge of approximately $2.2 million in the
fourth quarter of 1995 related to the discontinuance of its Unison
product line. The charge represents the write-off of previously
capitalized development costs, the write-down of assets used by
developers, the settlement of contractual obligations and severance
costs. The liability established was paid in the first quarter of
1996. A summary of these costs follows:
Total
Restructuring Noncash Accrued
Costs Costs Costs
Write-off of $1,608,163 $1,608,163 $-
capitalized software.
Severance ........ 269,849 - 269,849
Write-down of assets.. 109,559 109,559 -
Other costs..... 176,891 - 176,891
Total restructuring
charges...... $2,164,462 $1,717,722 $446,740
5. Income Taxes
The CompanyOs operating results for periods prior to June 1, 1994
were included in the consolidated income tax return of E&S.
Accordingly, E&S has already realized the full benefit of the
Company's operating loss carryforwards in its consolidated tax
return for periods through May 31, 1994. The Company's tax
provision for 1994 included the recognition of a $403,000 federal
tax benefit related to losses incurred by the Company during the
first five months of 1994. E&S compensated the Company for this
benefit in accordance with the tax sharing provisions of the
Distribution Agreement between the Company and E&S in conjunction
with the Distribution.
The components of income (loss) before taxes for the years ended
were as follows:
1996 1995 1994
Domestic........... $2,523,411 $(1,694,827) $539,864
Foreign............ 188,805 (340,327) (2,357)
$2,712,216 $(2,035,154) $537,507
The components of income tax expense (benefit) for the years ended
were as follows:
1996 1995 1994
Current tax expense (benefit)
Federal................ $71,000 $- $(133,035)
State and local........ 87,000 - (10,873)
Foreign................. 313,000 107,000 113,264
Total current....... 471,000 107,000 (30,644)
Deferred tax expense
(benefit) 289,000 (446,431) 216,431
Total provision(benefit) $760,000 $(339,431) $185,787
The difference between the effective income tax rate and the U.S.
federal income tax rate for the years ended is explained
as follows:
1996 1995 1994
Tax at U.S. federal
statutory rate......... 34.00% (34.00)% 34.00%
Foreign subsidiary losses
for which there is no
current tax benefit...... - - 18.30
Effect of foreign operations
(net of foreign taxes)...... 0.48 2.36 3.13
Effect of E&S tax sharing
agreement... - - (23.27)
Valuation allowance......... (10.73) 18.26 -
Other...................... 4.25 (3.25) 2.76
28.00% (16.63)% 34.92%
The tax effects of temporary differences that give rise to
deferred tax assets and liabilities at the end of each year are
summarized as follows:
1996 1995
Current deferred income tax asset:
Allowance for doubtful accounts.... $23,000 $7,000
Vacation accrual.................. 73,000 87,000
Customer deposits.................. 11,000 116,000
NOL carryforward.................. 143,000 611,000
Other................. ....... 11,000 -
Tax credit carryforward........... - 203,000
Valuation allowance................ (143,000) (414,000)
$118,000 $610,000
Noncurrent deferred income tax
liability:
Capitalized development costs...... $(678,000) $(840,000)
Property and equipment............ 51,000 55,000
Other..... ................... 25,000 -
Valuation allowance............... - (20,000)
$(602,000) $(805,000)
Income tax payments for 1996 and 1995 were $262,000 and $197,000,
respectively.
One of the Company's foreign subsidiaries has a loss carryforward
at December 31, 1996, of approximately $420,000 that has no
expiration date. For financial statement purposes, a valuation
allowance has been established to offset the deferred tax asset of
this loss carryforward.
Undistributed earnings of subsidiaries outside the United States
are considered to be permanently invested. Accordingly, no
provision for U.S. income taxes was made for undistributed earnings
of such subsidiaries, which aggregated $103,000 and $26,000 at
December 31, 1996 and 1995, respectively.
6. Stock Plans
In 1994, the Company adopted the 1994 Employee Stock Purchase
Plan, which provides for eligible employees to purchase stock at the
lower of 85% of the fair market value of the stock on the enrollment
date or exercise date as defined by the plan. Pursuant to the plan,
employee purchases are limited to 10% of compensation. The plan,
which has 150,000 shares of common stock reserved for issuance, is
in effect for ten years unless terminated or amended sooner by the
Board of Directors. At December 31, 1996, 64,232 shares have been
purchased under this plan.
In 1994, the Company adopted the 1994 Stock Plan which is
administered by the Compensation Committee and provides for
incentive stock options, nonstatutory stock options and stock
purchase rights to be granted to employees and consultants of the
Company. Pursuant to the plan, incentive stock options can be
exercised at a price which is not less than the fair value of the
stock on the grant date,and nonstatutory stock options and stock
purchase rights can be exercised at a price which is determined by
the Compensation Committee. The Compensation Committee is
responsible for establishing the period over which options and
rights can be exercised. Options vest at the rate of 25% on the
first anniversary of each grant and 1/48th per month over the next
three years. All options granted have 10 year terms. The plan,
which has 704,000 shares of common stock reserved for issuance, is
in effect for ten years unless terminated or amended sooner by the
Board of Directors.
In 1994, the Company adopted the 1994 Director Option Plan which
provides for nonstatutory stock options to be granted to nonemployee
directors at the fair market value of the stock at the date of grant.
Options can be exercised in 25% increments on the anniversary of its
date of grant. The plan, which was amended in 1996 to increase the
number of shares of common stock reserved for issuance from 100,000 to
300,000, is in effect for ten years unless terminated or amended sooner
by the Board of Directors.
The Company has elected to follow APB 25, "Accounting for Stock
Issued to Employees", and related interpretations in accounting for
its employee and nonemployee director stock options because, as
discussed below, the alternative fair value accounting provided for
under SFAS 123, "Accounting for Stock-Based Compensation", requires
use of option valuation models that were not developed for use in
valuing employee stock options. Under APB 25, because the exercise
price of the Company's employee and nonemployee director stock
options equals the market price of the underlying stock on the date
of grant, no compensation expense is recognized.
Pro forma information regarding net income and earnings per share
is required by SFAS 123 and has been determined as if the Company
had accounted for its employee and nonemployee director stock
options under the fair value method of that Statement. The fair
value for these options was estimated at the date of grant using a
Black-Scholes option pricing model with the following weighted
average assumptions: risk-free interest rates ranging from 5.62% to
7.83% for 1995 and 5.13% to 6.64% for 1996; volatility factor of .85
for both years; and a weighted average expected life of the option
of 5.3 years. For the Company's Employee Stock Purchase Plan,
compensation expense was also estimated using a Black-Scholes option
pricing model with the following assumptions: risk-free interest
rates ranging from 5.57% to 6.38% for 1995 and 5.05% to 5.25% for
1996; volatility factor of .85 for both years; and a weighted
average expected life of the option of 6 months.
The Black-Scholes option valuation model was developed for use in
estimating the fair value of traded options which have no vesting
restrictions and are fully transferrable. In addition, option
valuation models require the input of highly subjective assumptions
including the expected stock price volatility. Because the
Company's employee and nonemployee director stock options have
characteristics significantly different from those of traded options
and because changes in the subjective input assumptions can
materially affect the fair value estimate, in management's opinion,
the existing models do not necessarily provide a reliable single
measure of the fair value of its employee and nonemployee director
stock options.
For purposes of pro forma disclosures, the estimated fair value
of the options is amortized to expense over the options' vesting
period. The Company's pro forma information follows (in thousands
except for earnings per share information):
Pro Forma 1996 1995
Pro forma income(loss) $1,482 $(1,875)
Pro forma earnings
(loss) per share:
Primary $0.46 $(0.66)
Fully diluted $0.45 $(0.66)
Options 1996 Weighted 1995 Weighted
Outstanding Average Average
Summary Shares Exercise Shares Exercise
Price Price
Beginning 656,830 $5.2366 520,408 $5.3108
outstanding
Granted:
Price = Fair Value 215,700 $8.4899 159,850 $5.1039
Exercised (98,677) $5.8116 (3,133) $5.6413
Canceled/expired (15,469) $6.1574 (20,295) $6.0307
Ending outstanding 758,384 $6.0683 656,830 $5.2366
Exercisable at end
of year 275,438 218,832
12/31/96 Options Outstanding Options Exercisable
Weighted Weighted Weighted
Range of Average Average Average
Exercise Number Remaining Exercise Number Exercise
Prices Outstanding Life Price Exercisable Price
$4.2500-5.0000 470,676 7.56 $4.8429 249,186 $4.8747
5.7500-7.0000 49,617 8.93 $6.2502 5,410 $6.1032
7.0849-9.1805 218,091 8.68 $7.9155 20,842 $7.5250
12.000-16.6250 20,000 9.83 $14.3125 0 $0.0000
4.2500-16.6250 758,384 8.03 $6.0683 275,438 $5.0994
12/31/95 Options Outstanding Options Exercisable
Weighted Weighted Weighted
Range of Average Average Average
Exercise Number Remaining Exercise Number Exercise
Prices Outstanding Life Price Exercisable Price
$4.2500-5.0000 507,338 8.56 $4.8432 142,157 $4.9892
5.7500-6.2900 108,450 4.15 $6.2323 67,046 $6.2859
7.0849-9.1805 41,042 6.98 $7.4688 9,629 $7.6239
4.2500-9.1805 656,830 7.73 $5.2366 218,832 $5.5025
In January 1996, the Board of Directors of the Company authorized
and declared a dividend of one preferred share purchase right (a
"right") for each share of common stock outstanding on January 26,
1996. Each right represents the right to purchase one preferred
share of stock. These rights can be exercised only if certain
events occur, which include, among other things, when a beneficial
owner of the Company's common stock acquires a total of 20% or more
of the outstanding common stock of the Company.
7. Benefit Plan
In 1994, the Company established a defined contribution 401(k)
Plan covering all domestic employees who are at least 21 years of
age and have completed at least six months of service (provided that
such service represents a minimum of 1,000 hours worked). Employees
may contribute to the plan up to 17% of their compensation, which is
further limited by law ($9,500 in 1996). The Company will match
employee contributions for an amount up to 50% of the first 6% of
each employeeOs compensation deferral. Contributions made by the
Company were $152,282 in 1996 and $131,855 in 1995.
8. Geographic Segment Data
The CompanyOs foreign operations historically have been conducted
principally through the CompanyOs wholly owned foreign subsidiaries
and through E&S prior to June 1994. Information regarding
operations in different geographic areas for 1996, 1995 and 1994 is
as follows :
1996 United Europe Pacific Other Total
States Rim
Net sales ... $14,857,012 $10,935,292 $2,875,718 $118,371 $28,786,393
Operating
income....... $2,258,459 $45,744
Identifiable
assets...... $19,661,336 $4,847,698
1995 United Europe Pacific Other Total
States Rim
Net sales $10,516,419 $8,192,274 $2,132,607 $256,238 $21,097,538
Operating
loss......... $(2,078,136) $(406,553)
Identifiable
assets....... $15,111,389 $3,947,662
1994 United Europe Pacific Other Total
States Rim
Net sales $8,292,889 $9,345,780 $1,750,152 $212,776 $19,601,597
Operating
income....... $220,717 $89,075
Identifiable
assets....... $15,579,772 $5,553,767
Most services of the Company are provided on an integrated
worldwide basis. Because of the integration of U.S. and non-U.S.
services, it is not practical to separate precisely the U.S.-
oriented services from services resulting from operations outside
the United States and performed for customers outside the United
States; accordingly, the separation set forth in the preceding table
is based upon internal allocations, which involve certain management
judgments.
Net sales related to the Pacific Rim category and the Other
category in the preceding table represent export sales from the
United States to the respective category.
9. Concentrations of Credit Risk
Financial instruments that potentially subject the Company to
concentrations of credit risk consist principally of investments and
trade receivables. The Company invests available cash in bank
deposits, investment-grade securities, and short-term interest-
producing investments, including government obligations and other
money market instruments. The Company has adopted credit policies
and standards to evaluate the risk associated with its sales and
requires collateral, such as letters of credit and bank guarantees,
whenever deemed necessary. Management believes that any risk of
loss is significantly reduced due to the nature of the customers and
distributors with which it does business.
10. Commitments
The Company leases certain office facilities and equipment under
noncancelable operating leases with terms from one to four years.
Rent expense under such arrangements was $629,505, $730,825, and
$428,181 in 1996, 1995, and 1994, respectively. Noncancelable long-
term operating lease commitments are $823,382 for 1997, $589,498 for
1998, $471,183 for 1999 and $292,433 for 2000.
The Company is committed under royalty agreements to pay minimum
royalties of $60,000 in 1997.
11. Selected Quarterly Financial Data (Unaudited)
The following table presents unaudited financial data for each
quarter of 1996 and 1995
(in thousands, except per share data):
First Second Third Fourth
1996 Quarter Quarter Quarter Quarter
Total net sales................ $4,787 $6,819 $7,553 $9,627
Gross profit................... 3,160 4,308 5,209 6,119
Earnings (loss) from operations (356) 454 891 1,315
Net income (loss)............. (224) 397 688 1,091
Net income (loss) per share:
Primary.................. $(0.08) $0.13 $0.22 $0.32
Fully diluted........... - $0.13 $0.21 $0.32
First Second Third Fourth
1995 Quarter Quarter Quarter Quarter
Total net sales................ $4,836 $4,169 $5,330 $6,763
Gross profit................... 3,410 3,138 3,772 4,320
Income (loss) from operations.. (85) (619) (58) (1,723)
Net income (loss).............. 8 (308) 32 (1,428)
Primary net income (loss) per
share.................. $0.00 $(0.11) $0.01 $(0.49)
Report of Independent Auditors
Board of Directors and Shareholders
Tripos, Inc.
We have audited the accompanying consolidated balance sheets of
Tripos, Inc. as of December 31, 1996 and 1995, and the related
consolidated statements of operations, shareholders' equity and cash
flows for each of the three years in the period ended December 31,
1996. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on
these financial statements based on our audits.
We conducted our audits in accordance with generally accepted
auditing standards. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made
by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the 1996 and 1995 consolidated financial
statements referred to above present fairly, in all material respects,
the consolidated financial position of Tripos, Inc. at December 31,
1996 and 1995, and the consolidated results of its operations and its
cash flows for each of the three years in the period ended December 31,
1996, in conformity with generally accepted accounting principles.
ERNST & YOUNG LLP
St. Louis, Missouri
January 31, 1997
Selected Consolidated Financial Data
Year Year Year Year Year
ended ended ended ended ended
December December December December December
31, 31, 31, 31, 25,
1996 1995 1994 1993 1992
Consolidated Statements of Operations
In thousands, except per share amounts
Net Sales:
Software licenses....... $9,186 $8,651 $8,848 $8,467 $6,097
Support................. 6,715 6,510 5,564 4,380 3,726
Accelerated discovery
services................ 9,053 2,111 - - -
Hardware................ 3,832 3,825 5,190 5,130 3,657
Total net sales.......... 28,786 21,097 19,602 17,977 13,480
Cost of sales............ 9,990 6,458 6,416 5,845 4,808
Gross profit............. 18,796 14,639 13,186 12,132 8,672
Operating expenses:
Sales and marketing..... 10,566 9,951 8,259 7,343 6,278
Research and development 3,388 3,559 3,409 2,958 2,531
General and admin ...... 2,538 1,449 1,208 1,371 800
Restructuring charge.... - 2,165 - - -
Total operating expenses. 16,492 17,124 12,876 11,672 9,609
Income (loss) from
operations.............. 2,304 (2,485) 310 460 (937)
Other income(expense),net 408 450 228 (9) (11)
Income (loss) before
income taxes.......... 2,712 (2,035) 538 451 (948)
Income tax expense
(benefit).............. 760 (339) 186 7 121
Net income (loss)........ $1,952 $(1,696) $352 $444 $(1,069)
Primary earnings (loss)
per share (1)........ $0.61 $(0.59) $0.10 $0.08 -
Primary weighted average
number of shares.. 3,219 2,860 2,845 2,746 -
Fully diluted earnings
per share (1).... $0.59 - - - -
Fully diluted weighted
average number of shares. 3,289 - - - -
Consolidated Balance Sheet Data
(at year end) (2)
Working capital.......... $10,360 $8,638 $10,045 $2,847 $2,035
Due to parent............ $- $- $- $6,137 $4,324
Total assets............. $24,509 $19,059 $21,134 $12,115 $8,305
Total shareholders'
equity (deficit)......... $14,367 $11,322 $12,828 $(290) $217
(1) The earnings per share calculations for 1994 and 1993 are pro
forma calculations which reflect the effects of adjustments
to historical results of operations for estimates of the costs which
would have been incurred by Tripos during the respective periods
on a stand-alone basis.
(2) See Note 1 of the notes to consolidated financial statements for
discussion regarding the comparability of consolidated balance
sheet data.
Corporate Officers
John P. McAlister III James H. Munn
President and Chief European Controller
Executive Officer
Martin Bohl David E. Patterson
Vice President, European Senior Fellow
Operations
Richard D. Cramer III Mark W. Schwartz
Vice President, Scientific Vice President, Accelerated
Activities Discovery Services
W. Ward Davidson III Gregory B. Smith
Vice President, Sales Fellow
Robert C. Glen Martin Stuart
Vice President, Vice President, Sales-
Collaborative Discovery Americas & Pacific Rim
Services
John R. Hurst Paul L. Weber
Vice President, Discovery Vice President, Software
Software Science Development
Scott G. Hutton Mary P. Woodward
Vice President, Marketing Vice President, Business and
Strategic Relations
Colleen A. Martin John D. Yingling
Vice President, Chief United States Controller &
Financial Officer, Secretary Treasurer
Board of Directors
Ralph S. Lobdell Dr. John P. McAlister, III 3
Chairman of the Board of 1,2,4 Director of the Company
Directors of the Company since May, 1994
since June, 1994
President President and Chief
Harbour Group, Retired Executive Officer
Tripos, Inc.
Alfred Alberts 1,2,3,4 Gary Meredith 1,2,4
Director of the Company Director of the Company
since February, 1997 since January, 1996
Formerly Vice President of Senior Vice President and
Biochemistry and Natural Secretary
Product Discovery Evans & Sutherland Computer
Merck Research Laboratories Corporation
Stewart Carrell 1,2,4 Dr. Ferid Murad 1,2,3,4
Director of the Company Director of the Company
since May, 1994 since November, 1996
Chairman of the Board of Formerly Vice President of
Directors Pharmaceutical
Evans & Sutherland Computer Research & Development
Corporation Abbott Laboratories
1 Audit Committee
2 Compensation Committee
3 Technical Review Committee
4 Executive Committee
Corporate Information
Tripos, Inc. Annual Meeting of Shareholders
1699 South Hanley Road
St. Louis, Missouri 63144 The annual meeting will be held on
USA May 9, 1997. A formal notice of
(314) 647-1099 the meeting, with a proxy state-
URL http://www.tripos.com/ ment and form of proxy, is
scheduled to be mailed during the
week of April 7, 1997.
Transfer Agent and Registrar Market Information
Boatmen's Trust Company The Company's common stock was
St. Louis, Missouri 63178 initially listed for trading on
the Nasdaq National Market on
June 1, 1994. The following
table sets forth the high and low
sales prices for the Common stock
from January 1, 1995 through
Financial Reports December 31, 1996.
1996
The Company's 1996 Annual Report High Low
on Form 10-K is available to
shareholders upon request without First quarter..... $10.00 $6.75
charge. To obtain copies of the Second quarter.... $ 9.75 $6.00
Company's Form 10-K or copies Third quarter..... $11.875 $6.50
of the quarterly earnings releases Fourth quarter.... $19.25 $10.75
issued by the Company, please
write to Colleen A. Martin,
Tripos, Inc., 1699 South Hanley 1995
Road, St. Louis, MO, 63144. High Low
First quarter..... $6.25 $4.25
Second quarter.... $7.75 $5.50
Third quarter..... $6.75 $4.50
Independent Auditors Fourth quarter.... $8.50 $5.50
Ernst & Young LLP The Company had approximately 900
St. Louis, MO 63101 shareholders of record and 2,200
street name holders as of December
31, 1996. The Company has not
General Counsel declared or paid any dividends on
its Common stock. The Company
Peper, Martin, Jensen, Maichel currently intends to retain
and Hetlage earnings for use in its business,
St. Louis, MO 63101 therefore it does not anticipate
paying cash dividends in the
foreseeable future to common
Stock Symbol shareholders.
Tripos stock trades on the Nasdaq
National Market tier of the Nasdaq
Stock Market under the symbol
TRPS.
Sybyl, CoMFA, Triad, Unity, Legion, Selector, Alchemy, Optiverse,
BioSTAR and ChemSpace are trademarks of Tripos, Inc.
Exhibit 23.1
Consent of Independent Auditors
We consent to the incorporation by reference in this Annual Report
(Form 10-K) of Tripos, Inc. of our report dated January 31, 1997,
included in the 1996 Annual Report to Shareholders of Tripos, Inc.
Our audits also included the financial statement schedule of Tripos,
Inc. listed in Item 14 (a). This schedule is the responsibility of
the Company's management. Our responsibility is to express an
opinion based on our audits. In our opinion, the financial statement
schedule referred to above, when considered in relation to the basic
financial statements taken as a whole, presents fairly in all
material respects the information set forth therein.
We also consent to the incorporation by reference in the
Registration Statements (Form S-8, No. 33-79610) pertaining to the
Tripos, Inc. 1994 Stock Plan, the Tripos, Inc. 1994 Director Option
Plan and the Tripos, Inc. 1994 Employee Stock Purchase Plan and
(Form S-8, No. 333-09459) pertaining to the Tripos, Inc. 1996
Director Stock Compensation Plan and the amendment of the 1994
Director Option Plan of our report dated January 31, 1997 with
respect to the consolidated financial statements incorporated herein
by reference, and our report included in the preceding paragraph
with respect tot the financial statement schedule included in this
Annual Report (Form 10-K) of Tripos, Inc.
St. Louis, Missouri
March 24, 1997
<TABLE> <S> <C>
<ARTICLE> 5
<CIK> 0000920691
<NAME> TRIPOS, INC.
<MULTIPLIER> 1000
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-END> DEC-31-1996
<CASH> 8728
<SECURITIES> 0
<RECEIVABLES> 10635
<ALLOWANCES> 77
<INVENTORY> 29
<CURRENT-ASSETS> 19900
<PP&E> 6431
<DEPRECIATION> 5267
<TOTAL-ASSETS> 24509
<CURRENT-LIABILITIES> 9540
<BONDS> 0
0
0
<COMMON> 30
<OTHER-SE> 14337
<TOTAL-LIABILITY-AND-EQUITY> 24509
<SALES> 28786
<TOTAL-REVENUES> 28786
<CGS> 9991
<TOTAL-COSTS> 9991
<OTHER-EXPENSES> 16491
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> (425)
<INCOME-PRETAX> 2712
<INCOME-TAX> 760
<INCOME-CONTINUING> 1952
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 1952
<EPS-PRIMARY> .61
<EPS-DILUTED> .59
</TABLE>
